L&K BIOMED LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,980 KRW | -2.16% |
|
+7.43% | -1.96% |
| Sales 2024 * | 61.2B 44.19M | Sales 2025 * | 94.5B 68.23M | Capitalization | 199B 144M |
|---|---|---|---|---|---|
| Net income 2024 * | 9B 6.5M | Net income 2025 * | 19B 13.72M | EV / Sales 2024 * | 3.37 x |
| Net Debt 2024 * | 7.4B 5.34M | Net cash position 2025 * | 9B 6.5M | EV / Sales 2025 * | 2.01 x |
| P/E ratio 2024 * |
21.7
x | P/E ratio 2025 * |
10.2
x | Employees | 60 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.87% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.16% | ||
| 1 week | +7.43% | ||
| 1 month | +15.51% | ||
| 3 months | +34.86% | ||
| 6 months | +27.13% | ||
| Current year | -1.96% |
1 week
9 170.00
10 400.00
1 month
8 090.0010 400.00
Current year
7 110.0010 640.00
1 year
5 150.0012 620.00
3 years
5 150.0026 650.00
5 years
3 985.0062 500.00
10 years
3 985.0062 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Geun-Ju Park
CEO | Chief Executive Officer | 60 | 19-11-30 |
Gook-Jin Kang
CEO | Chief Executive Officer | 57 | 08-11-30 |
Hee-Bok Shin
AUD | Comptroller/Controller/Auditor | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gook-Jin Kang
CEO | Chief Executive Officer | 57 | 08-11-30 |
| Director/Board Member | 67 | - | |
Geun-Ju Park
CEO | Chief Executive Officer | 60 | 19-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 9,980 | -2.16% | 102,026 |
| 24-05-30 | 10,200 | -0.29% | 88,633 |
| 24-05-29 | 10,230 | +5.25% | 293,501 |
| 24-05-28 | 9,720 | +2.86% | 104,275 |
| 24-05-27 | 9,450 | +1.72% | 50,291 |
End-of-day quote Korea S.E., May 30, 2024
More quotes
L&K BIOMED CO., LTD. is a Korea-based company mainly engaged in the research, development and manufacture of medical devices. The Companyâs products consist of medical devices and medical equipment. Its medical devices include cervical spine products, such as cervical plate systems, cervical screw systems and cervical cage system, as well as thoracolumbar spine products and others. Its medical equipment includes three dimensional (3D) full-body scanners. It also engages in the bio-similar business, which develops cell engineering.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.96% | 144M | |
| +13.73% | 130B | |
| -8.17% | 10.99B | |
| +41.80% | 5.67B | |
| -21.94% | 4.72B | |
| +7.81% | 3.42B | |
| -10.26% | 2.76B | |
| -10.29% | 2.11B | |
| -13.58% | 1.92B | |
| -27.77% | 1.68B |
- Stock Market
- Equities
- A156100 Stock
